as attached

Date: 02 September 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: ANNUAL REPORT OF THE COMPANY FOR THE FY 2025-26 Dear Sir/Madam, Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report of the company for the Financial Year 2025-26 along with the Notice of the 20th Annual General Meeting of the Company scheduled to be held on Friday, September 25, 2026, at 11:00 A.M. (IST) through Video Conferencing (VC). The said Annual Report and the Notice of AGM are also being made available on the Company's website i.e. https://eris.co.in/ Kindly take the above information on your records. Yours faithfully, Eris Lifesciences Limited Milind Talegaonkar Company Secretary and Compliance Officer ICSI Membership No.: A26493 FORWARD- LOOKING STATEMENTS This report may contain some statements on the Company's business or financials which may be construed as forward-looking based on the management's plans and assumptions. The actual results may be materially different from these forward- looking statements although we believe we have been prudent in our assumptions. TABLE OF CONTENTS CORPORATE OVERVIEW 06-58 Insulins and GLP-1 – An evolving 10 Year Financial Highlights 29 “Moat” for your Company 06 Domestic Branded Formulations Business 30 Eris BioNxt – One of the largest Key Mother Brands 31 Biologics facilities in India 08 Prescription Ranks 32 Stepping up the pace on product innovation 09 Domestic Formulations Divisions 33 CMD’s Letter to Shareholders 10 Key Domestic Therapies 35 From the COO’s desk 12 India Distribution Network 45 From the CFO’s desk 14 International Business 47 Eris at a Glance – Who we are 16 Information Technology 49 Manufacturing – Ramping up our 18 Human Resources 50 Technology advantage 19 ESG at Eris 52 India Centric Studies 22 Environment and Occupational Safety 55 India Head and Neck Cancer Study 26 Awards and Accolades 57 Patient Care Initiatives 27 Our Investors 58 STATUTORY FINANCIAL REPORTS STATEMENTS 59-197 198-376 Management Discussion and Analysis 60 Standalone Financial Statements 198 Directors’ Report 70 Consolidated Financial Statements 284 Corporate Governance Report 98 Business Responsibility and Sustainability Report (BRSR) 141 Op. Revenue PAT (INR) (INR)^ EPS (INR)^ Cash EPS (INR)^ 3,129 648 46.7 63.2 cr cr 8% yoy growth 73% yoy growth EBITDA Dividend Payout Adjusted RoCE* RoE** (INR) Ratio^ 19 15 1,120 15 cr % 10% yoy growth * Excludes the impact of M&A related Amortisation **Excludes treasury investments, cash & cash equivalents and impact of Oneoff upside in PAT ^One-off upside Rs. 150 cr. from deferred tax adjustment in PAT Power of Empathy, Truth of Science INSULINS & GLP-1 – AN EVOLVING “MOAT” FOR YOUR COMPANY The exciting market opportunity in Insulins The Indian insulins market has been dominated by innovators for a long time. With significant complexities in product technology and manufacturing, storage and transport as well as patient service/ engagement, this Rs. 5,000+ crore p.a. market is a natural oligopoly and has always been a strategic adjacency to our established Diabetes franchise. Accordingly, we entered this market in March 2022 with the launch of two homegrown brands Xsulin and Xglar. We subsequently acquired insulin brands Basalog and Insugen from Biocon in April 2024. With four brands being promoted by two of our divisions, our Insulins franchise has scaled up significantly and is evolving into a source of long-term competitive advantage for us. RHI Cartridges – We have tripled our market share from 8% to 25% since the Biocon acquisition RHI Cartridges - Eris market share by sales Apr 24 Sep 25 Dec 25 RHI + Glargine – we have expanded our market share from 9% to 16% since the acquisition Total RHI + Glargine - Eris market sales +700 bps Apr 24 Sep 25 Dec 25 Our Bhopal facility places us in a strategically competitive position to serve the Indian insulin market. With a manufacturing capacity of 130+ millions vials p.a. and 75+ million cartridges p.a., this facility will enable us to have adequate control on supply and economics in the following product families: • Existing products – RHI and Glargine • Pipeline products – Degludec, Degludec-Liraglutide, Aspart, Aspart Mix, Aspart-Degludec On the back of our established front-end presence in Diabetes and our fully integrated Bhopal capabilities, we expect to be a strategically important player in the Indian insulin market, which is steadily moving away from innovators and into the hands of Indian companies. 06 Annual Report 2025-2026 Power of Empathy, Truth of Science Leading the India GLP-1 market from the front Semaglutide, a potential game-changer for the management of metabolic diseases, witnessed an LOE in India in March-26. In the first quarter (April-June ’26) post LOE, Eris achieved a market rank of #1 by sale volume and #2 by sale value in the flagship injectable product. Semaglutide Injection - Eris share by sale Units Semaglutide Injection - Eris share by sale Value 22% 22% 22% Mar 26 Apr 26 May 26 Jun 26 Mar 26 Apr 26 May 26 Jun 26 Our first quarter performance validates our thesis of being able to take a leading position in Gx Semaglutide based on the strength of our Insulins franchise • A long-standing and one-of-its kind patient care platform focused on developing and nurturing long-term relationships with patients • Credibility and market share with KOLs in Diabetes and Endocrinology • Established supply chain and experience with cold chain products With the in-house manufacturing of Semaglutide vials and cartridges all set to commence from H2 of FY27, we expect significant tailwinds in our competitive position going forward. Between our existing Insulin franchise, our upcoming pipeline of Insulin Analogs and our GLP-1 platform, we see the Injectable Diabesity business evolving into a long-term strategic “moat” for Eris. Annual Report 2025-2026 07 Power of Empathy, Truth of Science ERIS BIONXT BHOPAL – ONE OF THE LARGEST BIOLOGICS FACILITY IN INDIA Eris BioNxt, a manufacturing facility in Bhopal that started as an insulin backward integration play for us in Oct 2024 has evolved into an important source of competitive advantage for us. We acquired the facility for Rs. 105 crore in Oct-24 and have subsequently invested Rs. 200+ crore to expand and upgrade it to be able to manufacture a wide range of biologics dosage forms across Insulins, GLP-1 and monoclonal antibodies. Manufacturing capacities Line Current Capacity Status Capacity addition underway Total capacity p.a. Vials 25 million p.a. Commissioned in Aug-25 108 million p.a. (Q3 FY27) 133 million Cartridge 30 million p.a. Commissioning in Q2-FY27 45 million p.a. (Q3 FY27) 75 million mAbs vials 12 million p.a. Commissioning in Q4 FY27 — 12 million mABs PFS 12 million p.a. Commissioning in Q4 FY27 — 12 million Product portfolio (existing and pipeline) • Insulins: Insulin Glargine (rDNA), Biphasic Isophane 50/50 & 30/70, Isophane (NPH), Soluble Insulin -100/40 IU/mL across 3–10 mL packs. • Insulin Analogs: Degludec, Degludec-Liraglutide, Aspart, Aspart Mix, Aspart-Degludec • GLP-1: Semaglutide Vials and Cartridges • Oncology/ Hormones: Teriparatide, Romiplostim • Monoclonal Antibodies: Trastuzumab, Bevacizumab, Nimotuzumab, Denosumab Eris BioNxt is positioned to scale into an exciting biologics manufacturing platform, reinforcing our long-term commitment to move up the value chain and bring world class technology and products to our patients in India. 08 Annual Report 2025-2026 Power of Empathy, Truth of Science STEPPING UP THE PACE ON PRODUCT INNOVATION Our Research and Development (R&D) program serves as the cornerstone of our growth strategy, and is anchored in the development of complex specialty products, recombi [Showing first 8,000 characters — download PDF for full document]